Co-Authors
This is a "connection" page, showing publications co-authored by MICHAEL ANDREEFF and VENKATA LOKESH BATTULA.
Connection Strength
2.866
-
IKK inhibition by BMS-345541 suppresses breast tumorigenesis and metastases by targeting GD2+ cancer stem cells. Oncotarget. 2017 Jun 06; 8(23):36936-36949.
Score: 0.622
-
Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest. 2012 Jun; 122(6):2066-78.
Score: 0.438
-
Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy. Haematologica. 2023 06 01; 108(6):1500-1514.
Score: 0.235
-
Maximal Activation of Apoptosis Signaling by Cotargeting Antiapoptotic Proteins in BH3 Mimetic-Resistant AML and AML Stem Cells. Mol Cancer Ther. 2022 06 01; 21(6):879-889.
Score: 0.220
-
Ganglioside GD2: a novel therapeutic target in triple-negative breast cancer. Ann N Y Acad Sci. 2022 02; 1508(1):35-53.
Score: 0.210
-
Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2+ breast cancer stem-like cells. J Immunother Cancer. 2021 03; 9(3).
Score: 0.201
-
Bone marrow stromal cells induce an ALDH+ stem cell-like phenotype and enhance therapy resistance in AML through a TGF-?-p38-ALDH2 pathway. PLoS One. 2020; 15(11):e0242809.
Score: 0.198
-
Osteogenic niche in the regulation of normal hematopoiesis and leukemogenesis. Haematologica. 2018 12; 103(12):1945-1955.
Score: 0.171
-
Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-?B mediates chemoresistance. Blood. 2014 Apr 24; 123(17):2691-702.
Score: 0.124
-
Human extramedullary bone marrow in mice: a novel in vivo model of genetically controlled hematopoietic microenvironment. Blood. 2012 May 24; 119(21):4971-80.
Score: 0.109
-
Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells. 2010 Aug; 28(8):1435-45.
Score: 0.097
-
Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct Target Ther. 2022 Apr 01; 7(1):110.
Score: 0.054
-
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct Target Ther. 2022 02 21; 7(1):51.
Score: 0.054
-
CXCR4 Inhibition Enhances Efficacy of FLT3 Inhibitors in FLT3-Mutated AML Augmented by Suppressed TGF-b Signaling. Cancers (Basel). 2020 Jun 30; 12(7).
Score: 0.048
-
GD2 and GD3 synthase: novel drug targets for cancer therapy. Mol Cell Oncol. 2015 Jul-Sep; 2(3):e975068.
Score: 0.033
-
Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth. Ann Hematol. 2014 Mar; 93(3):485-492.
Score: 0.030
-
Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells. 2009 Oct; 27(10):2614-23.
Score: 0.023